Minimizing Risks Is Not Enough: The Relevance of Benefits to Protecting Research Participants
- PMID: 33416657
- PMCID: PMC10084491
- DOI: 10.1353/pbm.2020.0023
Minimizing Risks Is Not Enough: The Relevance of Benefits to Protecting Research Participants
Abstract
Forty years ago, the Belmont Report counseled that a "systematic, nonarbitrary analysis of risks and benefits" is vital to ensuring the ethical appropriateness of research with human subjects. Since then, research ethics has devoted considerable attention to the first half of this advice, emphasizing the ethical importance of assessing and minimizing the risks of research with human subjects. Significantly less attention has been devoted to a systematic assessment of the potential benefits of research participation. To the extent that benefits for individual participants are considered at all, commentators tend to focus on their potential to undermine the goal of minimizing risks. A chance for clinical benefit may obscure the fact that research poses risks not present in clinical care, while an offer of financial compensation or ancillary care may induce individuals to accept risks that conflict with their long-term interests. This article argues that, while undoubtedly important, minimizing risks fails to offer sufficient protection for research participants, especially those who cannot consent, because it neither ensures that the risks of research are justified nor protects participants from exploitation. Belmont's advice to develop systematic and nonarbitrary ways to ensure that research participants receive appropriate benefits needs to be heeded as well.
Similar articles
-
Towards Identifying an Upper Limit of Risk: A Persistent Area of Controversy in Research Ethics.Perspect Biol Med. 2020;63(2):327-345. doi: 10.1353/pbm.2020.0022. Perspect Biol Med. 2020. PMID: 33416656
-
Informed Consent, Therapeutic Misconception, and Unrealistic Optimism.Perspect Biol Med. 2020;63(2):359-373. doi: 10.1353/pbm.2020.0024. Perspect Biol Med. 2020. PMID: 33416658
-
The ethics and governance of medical research: what does regulation have to do with morality?New Rev Bioeth. 2003 Nov;1(1):41-58. doi: 10.1080/1740028032000131413. New Rev Bioeth. 2003. PMID: 15706668 No abstract available.
-
[Informed consent: a dialogic praxis for the research].Rev Invest Clin. 2009 Jan-Feb;61(1):73-82. Rev Invest Clin. 2009. PMID: 19507477 Free PMC article. Review. Spanish.
-
Best practice & research in anaesthesiology issue on new approaches in clinical research ethics in clinical research.Best Pract Res Clin Anaesthesiol. 2011 Dec;25(4):569-82. doi: 10.1016/j.bpa.2011.08.003. Best Pract Res Clin Anaesthesiol. 2011. PMID: 22099922 Review.
References
-
- Charlton V, et al. 2017. “Cost Effective but Unaffordable: An Emerging Challenge for Health Systems.” BMJ 356: j1402. - PubMed
-
- DiMasi J, Grabowski HG, and Hansen RW. 2016. “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.” J Health Econ 47: 20–33. - PubMed
-
- Goozner M, 2014. “Why Sovaldi Shouldn’t Cost $84,000.” Mod Healthc 44 (18): 26. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources